Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention
| العنوان: | Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention |
|---|---|
| المؤلفون: | Urban, Philip, Mehran, Roxana, Colleran, Roisin, Angiolillo, Dominick J, Byrne, Robert A, Capodanno, Davide, Cuisset, Thomas, Cutlip, Donald, Eerdmans, Pedro, Eikelboom, John, Farb, Andrew, Gibson, C Michael, Gregson, John, Haude, Michael, James, Stefan K, Kim, Hyo-Soo, Kimura, Takeshi, Konishi, Akihide, Laschinger, John, Leon, Martin B, Magee, PF Adrian, Mitsutake, Yoshiaki, Mylotte, Darren, Pocock, Stuart, Price, Matthew J, Rao, Sunil V, Spitzer, Ernest, Stockbridge, Norman, Valgimigli, Marco, Varenne, Olivier, Windhoevel, Ute, Yeh, Robert W, Krucoff, Mitchell W, Morice, Marie-Claude |
| المساهمون: | Hôpital de la Tour, Cardiovascular Research Foundation, Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), University of Florida [Gainesville] (UF), University of Catania [Italy], Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Beth Israel Deaconess Medical Center [Boston] (BIDMC), Harvard Medical School [Boston] (HMS), AUTRES, McMaster University [Hamilton, Ontario], U.S. Food and Drug Administration (FDA), Beth Israel Deaconess Medical Center [Boston, USA], London School of Hygiene and Tropical Medicine (LSHTM), Lukaskrankenhaus, Uppsala University, Seoul National University Hospital, Kyoto University [Kyoto], Pharmaceuticals and Medical Devices Agency, Columbia University Medical Center (CUMC), Columbia University [New York], National University of Ireland [Galway] (NUI Galway), Scripps Clinic [San Diego, CA, USA], Duke Clinical Research Institute, Erasmus University Medical Center [Rotterdam] (Erasmus MC), University of Bern, Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Cardiovascular European Research Center, Hôpital Privé Jacques Cartier [Massy], Abbott Vascular, Alvimedica, Amgen, AstraZeneca, Biosensors, Biotronik, Boston Scientific, Celonova, Chiesi, Cordis, Daiichi Sankyo, Edwards Lifesciences, Janssen, Medinol, Medtronic, Orbusneich, Portola, Sanofi, Sinomed, Sahajanand Medical Technologies, and Terumo., Cardiology, Kyoto University, Prémilleux, Annick |
| المصدر: | Circulation Circulation, American Heart Association, 2019, 140 (3), pp.240-261. ⟨10.1161/CIRCULATIONAHA.119.040167⟩ Circulation, 140(3), 240-261. Lippincott Williams & Wilkins Circulation, 2019, 140 (3), pp.240-261. ⟨10.1161/CIRCULATIONAHA.119.040167⟩ |
| بيانات النشر: | HAL CCSD, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Paris, Consensus, [SDV]Life Sciences [q-bio], percutaneous coronary intervention, White Paper, Anticoagulants, Congresses as Topic, Risk Assessment, State of the Art, [SDV] Life Sciences [q-bio], District of Columbia, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, Humans, clinical trial protocols as topic, hemorrhage |
| الوصف: | Supplemental Digital Content is available in the text. Identification and management of patients at high bleeding risk undergoing percutaneous coronary intervention are of major importance, but a lack of standardization in defining this population limits trial design, data interpretation, and clinical decision-making. The Academic Research Consortium for High Bleeding Risk (ARC-HBR) is a collaboration among leading research organizations, regulatory authorities, and physician-scientists from the United States, Asia, and Europe focusing on percutaneous coronary intervention–related bleeding. Two meetings of the 31-member consortium were held in Washington, DC, in April 2018 and in Paris, France, in October 2018. These meetings were organized by the Cardiovascular European Research Center on behalf of the ARC-HBR group and included representatives of the US Food and Drug Administration and the Japanese Pharmaceuticals and Medical Devices Agency, as well as observers from the pharmaceutical and medical device industries. A consensus definition of patients at high bleeding risk was developed that was based on review of the available evidence. The definition is intended to provide consistency in defining this population for clinical trials and to complement clinical decision-making and regulatory review. The proposed ARC-HBR consensus document represents the first pragmatic approach to a consistent definition of high bleeding risk in clinical trials evaluating the safety and effectiveness of devices and drug regimens for patients undergoing percutaneous coronary intervention. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 0009-7322 1524-4539 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::d093dfd95ca7f7acc956bc75808aaff4Test https://hal-amu.archives-ouvertes.fr/hal-02542119/documentTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.pmid.dedup....d093dfd95ca7f7acc956bc75808aaff4 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 00097322 15244539 |
|---|